MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Jazz Pharmaceuticals plc Operating Cycle 2011-2026 | JAZZ
Annual Operating Cycle Jazz Pharmaceuticals plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.2 | 63.8 | 64.6 | 60.6 | 56.6 | 58.1 | 284 | 210 | 194 | 176 | 127 | 151 | 155 | 170 | 149 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 284 | 56.6 | 132 |
Quarterly Operating Cycle Jazz Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.9 | 59.6 | 70 | 61.5 | 62.6 | 67.5 | 58.1 | 58.8 | 65.2 | - | 29.2 | 28 | 63.7 | - | 54.8 | 55.9 | 60.9 | 54.4 | 60.2 | 64.3 | 64.2 | 55.8 | 60.4 | 60.8 | 55.6 | 50.5 | 51.3 | 48.1 | 50.1 | 46.9 | 49.7 | 51.9 | 55.6 | 53.9 | 57.1 | 56.1 | 60.3 | 56.1 | 56.1 | 57.3 | 58.4 | 51.8 | 55.5 | 58.4 | 57.5 | 48.3 | 49 | 54.7 | 46.6 | 37.5 | 39.2 | 55.4 | 48.9 | 37.5 | 42.8 | 48.6 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70 | 28 | 54.1 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 7.72 | 1.85 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
237 | $ 19.68 | 0.92 % | $ 920 M |  USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 14.5 | 0.03 % | $ 6.02 B |  Irlanda |
 |
GlaxoSmithKline plc
GSK
|
0.02 | $ 52.37 | 1.02 % | $ 173 B |  Britain |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Heron Therapeutics
HRTX
|
842 | $ 0.81 | 3.74 % | $ 135 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Benitec Biopharma
BNTC
|
141 | $ 11.05 | 0.64 % | $ 455 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Incyte Corporation
INCY
|
145 | $ 90.36 | -0.47 % | $ 17.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
313 | $ 0.74 | -9.75 % | $ 1.81 M | Canada |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.43 | 4.6 % | $ 735 M | Canada |